Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPanthera Res. Regulatory News (PAT)

Share Price Information for Panthera Res. (PAT)

Share Price is delayed by 15 minutes
Get Live Data
18.50    -0.10 (-0.55%)
Bid:
18.00
Ask:
19.00
Spread: 1.00 (5.556%)
Market Cap: £47.12m
PAT Live PriceLast checked at - London Stock Exchange

Intraday Panthera Res. Share Chart

Equity Financing Update

18 Dec 2023 07:38

RNS Number : 1297X
Panthera Resources PLC
18 December 2023
 

THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

18 December 2023

 

Panthera Resources Plc

("Panthera" or "the Company")

 

Equity Financing Update

Subscription to raise £150k in addition to the £785k recently raised

 

Panthera Resources plc (AIM: PAT), the gold exploration and development company with assets in India and West Africa, is pleased to announce that it has conditionally raised an additional £150,000 (before expenses) by way of a subscription (the "Additional Equity Financing") of a total of 3,000,000 new ordinary shares of 1 pence each in the Company (the "Ordinary Shares") at a price of 5 pence per new Ordinary Share (the "Subscription Price").

 

This follows the completion of the equity capital fundraise for £785,000 (before expenses), details of which were announced by the Company on 6 December 2023 (together the "Initial Equity Financing"). In this respect, considering that the Initial Equity Financing was substantially oversubscribed, the Company has elected to extend the Initial Equity Financing through raising an additional £150,000 (before expenses) at the Subscription Price, being a small part of the oversubscriptions.

 

It is intended that the net proceeds of the Additional Equity Financing will be deployed for the same purposes as that of the Initial Equity Financing, namely, towards the Company's activities in India and West Africa and meeting the Company's working capital commitments.

 

The Additional Equity Financing has been conducted as a private subscription under the Company's existing allotment and pre-emption disapplication authorities and participation has not been made available to members of the public. The 3,000,000 new Ordinary Shares (the "Subscription Shares") will rank pari passu with the existing Ordinary Shares.

 

The Additional Equity Financing is subject to terms and conditions agreed between the Company and the subscriber for the Subscription Shares and is conditional, inter alia, on Admission (as defined below). The Additional Equity Financing is not underwritten by Allenby Capital Limited ("Allenby Capital") or any other person.

 

The Company has agreed to pay Allenby Capital a fundraise commission in connection with funds introduced by Allenby Capital pursuant to the Additional Equity Financing. In addition, the Company has agreed to issue 180,000 options to Allenby Capital, exercisable at a price of 5 pence on or before 14 December 2025 ("Option") with each Option entitling the holder to acquire one new Ordinary Share upon exercise of the Option.

 

Admission and total voting rights

 

Application will be made to London Stock Exchange plc for the 3,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is currently anticipated that Admission will become effective and that dealings will commence on AIM at 8.00 a.m. on or around 21 December 2023.

 

Upon Admission of the 3,000,000 new Ordinary Shares, the Company's issued ordinary share capital will consist of 173,989,083 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 173,989,083. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Contacts

 

Panthera Resources PLC

Mark Bolton (Managing Director) +61 411 220 942

contact@pantheraresources.com

 

Allenby Capital Limited (Nominated Adviser & Joint Broker) +44 (0) 20 3328 5656

John Depasquale / Vivek Bhardwaj (Corporate Finance)

Guy McDougall / Kelly Gardiner (Sales & Corporate Broking)

 

Novum Securities Limited (Joint Broker) +44 (0) 20 7399 9400

Colin Rowbury

 

Financial Public Relations

Zak Mir +44 (0) 786 752 7659

 

Subscribe for Regular Updates

 

Follow the Company on Twitter at: @PantheraPLC

 

For more information and to subscribe to updates visit: pantheraresources.com

 

Forward-looking Statements

This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterised by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "suggest", "indicate" and other similar words or statements that certain events or conditions "may" or "will" occur. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such factors include, among others: the actual results of current exploration activities; conclusions of economic evaluations; changes in project parameters as plans continue to be refined; possible variations in ore grade or recovery rates; accidents, labour disputes, and other risks of the mining industry; delays in obtaining governmental approvals or financing; and fluctuations in metal prices. There may be other factors that cause actions, events, or results not to be as anticipated, estimated, or intended. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly, undue reliance should not be put on such statements due to the inherent uncertainty therein.

 

Notice to Distributors

 

Solely for the purposes of the product governance requirement contained in Chapter 3 of the FCA Product Intervention and Product Governance Sourcebook (together, the "UK Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Subscription Shares have been subject to a product approval process, which has determined that the Subscription Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, as defined under the FCA Handbook Conduct of Business Sourcebook, and (ii) eligible for distribution through all permitted distribution channels (the "Target Market Assessment").

 

Notwithstanding the Target Market Assessment, distributors should note that: the price of the Subscription Shares may decline and investors could lose all or part of their investment; the Subscription Shares offer no guaranteed income and no capital protection; and an investment in the Subscription Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Subscription Shares. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Allenby Capital Limited will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of the FCA Handbook Conduct of Business Sourcebook COBS 9A and 10A respectively; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Subscription Shares.

 

Each distributor is responsible for undertaking its own target market assessment in respect of the Subscription Shares and determining appropriate distribution channels.

 

**ENDS**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIUWOBROOUUARA
Date   Source Headline
3rd Jun 20267:00 amRNS-ROnline Investor Webinar
29th May 20265:15 pmRNSTotal Voting Rights
21st May 20267:00 amRNSConversion of Options
6th May 20267:00 amRNSConversion of Options
30th Apr 20265:00 pmRNSTotal Voting Rights
14th Apr 20267:09 amRNSConversion of Options
9th Apr 20262:31 pmRNSIssue of Equity – In Lieu of Director Fees
2nd Mar 20267:00 amRNSArbitration Update
19th Jan 20267:00 amRNSBido Drilling Results
31st Dec 202512:45 pmRNSTotal Voting Rights
31st Dec 202512:45 pmRNSTotal Voting Rights
29th Dec 20257:00 amRNSHalf-year Financial Report
29th Dec 20257:00 amRNSHalf-year Financial Report
11th Dec 20257:00 amRNSWarrant Conversion
3rd Dec 20257:00 amRNSWarrant Conversion
1st Dec 20257:00 amRNSTotal Voting Rights
25th Nov 20258:59 amRNSWarrant Conversion
21st Nov 20257:00 amRNSKalaka Metallurgical Study Results
20th Nov 20252:00 pmRNSWarrant Conversion
17th Nov 20257:00 amRNSOTCQB Approval
12th Nov 20257:00 amRNSOTC Application
3rd Nov 202511:02 amRNSIssue of Equity - Warrant Conversion and Fees
31st Oct 20255:05 pmRNSTotal Voting Rights
29th Oct 20257:00 amRNSArbitration Update
16th Oct 20255:05 pmRNSWarrant Conversion
9th Oct 202510:31 amRNSWarrant Conversion
8th Oct 20257:00 amRNSArbitration Financing Facility Update
3rd Oct 202511:30 amRNSResult of AGM
29th Sep 20257:00 amRNSChange of Registered Office
18th Sep 20257:00 amRNSArbitration Update
29th Aug 20255:00 pmRNSTotal Voting Rights
27th Aug 20257:58 amRNS2025 Annual Financial Report
8th Aug 20257:00 amRNSOption Conversion
4th Aug 20257:00 amRNSCommencement of Cascades Feasibility Study
25th Jul 20257:32 amRNSWarrant Conversion
18th Jul 20257:00 amRNSBido Drilling
19th May 20257:00 amRNSUS$1.58 billion Claim for Damages
30th Apr 20255:00 pmRNSTotal Voting Rights
16th Apr 20253:54 pmRNSIssue of Equity - Warrant Conversion and Fees
31st Mar 20255:00 pmRNSTotal Voting Rights
27th Mar 20257:00 amRNSIssue of Equity - Conversion of Options
20th Mar 202510:37 amRNSWarrant Exercise
7th Mar 20255:35 pmRNSNotification of Major Holding
6th Mar 20254:45 pmRNSUpdate on Issue of Equity Fundraising
28th Feb 20255:32 pmRNSNotification of Major Holding
25th Feb 20257:47 amRNSResult of Placing and Subscription
24th Feb 20255:04 pmRNSIssue of Equity
21st Feb 20255:00 pmRNSWarrant Exercise
20th Feb 20256:11 pmRNSNotifications of Major Holdings
4th Feb 20257:00 amRNSMaiden JORC Resource Estimate for Kalaka Project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.